NCT01684397 2026-02-27
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
20 trialsNCT05180695 2026-02-10
AMPHISARC
Centre Leon Berard
Phase 1/2 Active not recruiting
NCT06239272 2026-01-26
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05210413 2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2 Active not recruiting
NCT02331498 2025-05-20
PAZOGLIO
Centre Antoine Lacassagne
Phase 1/2 Recruiting
NCT03660930 2025-04-30
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
University of Washington
Phase 1/2 Terminated
NCT06895733 2025-03-26
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Tianjin Medical University Second Hospital
Phase 1/2 Recruiting
NCT02601209 2022-08-23
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02303028 2022-06-28
TOPAZ
The Hospital for Sick Children
Phase 1/2 Completed
NCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT01465659 2021-08-05
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Northwestern University
Phase 1/2 Completed
NCT02055690 2021-05-17
PAZOFOS
The Christie NHS Foundation Trust
Phase 1/2 Terminated
NCT01975519 2020-05-20
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT03628131 2018-09-19
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
Samsung Medical Center
Phase 1/2 Unknown
NCT01418001 2018-01-11
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01600573 2016-10-11
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Charite University, Berlin, Germany
Phase 1/2 Unknown
NCT01719302 2016-06-16
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
University of Vermont
Phase 1/2 Completed
NCT01238770 2016-02-10
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
University Hospital Heidelberg
Phase 1/2 Completed
NCT01716546 2015-10-08
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
Hellenic Oncology Research Group
Phase 1/2 Terminated
NCT01265940 2012-10-10
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Lukas-Krankenhaus GmbH
Phase 1/2 Completed